AGIO Stock: Price, Forecast, Financials & AI Analysis

High

Open

VWAP

Vol

Mkt Cap

Low

Amount

EV/EBITDA(TTM)

Total Shares

EV/OCF(TTM)

P/S(TTM)

Market Estimates

Earnings Estimates

Revenue

YoY Chg

EPS

YoYChg

FY2025Q4

FY2026Q1

FY2026Q2

11.70M

+9.03%

-1.954

+12.32%

16.64M

+90.68%

-1.839

+18.65%

21.49M

+72.57%

-1.805

-6.5%

Estimates Revision

The market is revising Upward the revenue expectations for Agios Pharmaceuticals, Inc. (AGIO) for FY2025, with the revenue forecasts being adjusted by 3.39% over the past three months. During the same period, the stock price has changed by -33.04%.

Revenue Estimates for FY2025

Revise Upward

+3.39%

In Past 3 Month

EPS Estimates for FY2025

Revise Downward

-4.68%

In Past 3 Month

Stock Price

Go Down

-33.04%

In Past 3 Month

7 Analyst Rating

Wall Street analysts forecast AGIO stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for AGIO is 31.17 USD with a low forecast of 20.00 USD and a high forecast of 48.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

4 Buy

3 Hold

0 Sell

Moderate Buy

Current: 0.000

Low

20.00

Averages

31.17

High

48.00

Current: 0.000

Low

20.00

Averages

31.17

High

48.00

JPMorgan

Neutral

maintain

$20 -> $25

2026-01-06

New

Reason

JPMorgan

Price Target

$20 -> $25

2026-01-06

New

maintain

Neutral

Reason

JPMorgan raised the firm's price target on Agios Pharmaceuticals to $25 from $20 and keeps a Neutral rating on the shares. The firm updated the company's model post the approval of Aqvesme.

BofA

Buy

maintain

$34 -> $35

2026-01-06

New

Reason

BofA

Price Target

$34 -> $35

2026-01-06

New

maintain

Buy

Reason

BofA raised the firm's price target on Agios Pharmaceuticals to $35 from $34 and keeps a Buy rating on the shares. The firm is updating its price targets for U.S Biopharmaceuticals under its coverage, the analyst tells investors. Over the past few months, several key items "have fallen into place," including positive data catalysts being rewarded; large-cap biopharma spending cash on M&A and in-licensing; growing backlog of companies on the private side; improving access to capital; and limited impact from drug price regulation, BofA says. The firm believes biotech is back, but the biggest concern is whether this will last.

Citi

analyst

Buy

maintain

$38

2025-12-26

Reason

Citi

analyst

Price Target

$38

2025-12-26

maintain

Buy

Reason

Citi closed the firm's "upside 30-day catalyst watch" on Agios Pharmaceuticals following FDA approval of Aqvesme with a broad label for the treatment of both transfusion-dependent and non-transfusion-dependent thalassemia. Given that Aqvesme has a REMS requiring liver monitoring every four weeks during the first 24 weeks of treatment, as expected, the firm thinks the early launch will be gradual, but anticipates an acceleration as patient starts normalize, says the analyst, who keeps a Buy rating and $38 price target on Agios shares.

Leerink

Outperform

maintain

$34 -> $40

2025-12-26

Reason

Leerink

Price Target

$34 -> $40

2025-12-26

maintain

Outperform

Reason

Leerink raised the firm's price target on Agios Pharmaceuticals to $40 from $34 and keeps an Outperform rating on the shares. The firm notes that on Tuesday, Agios announced that the Food and Drug Administration approved mitapivat for the treatment of anemia in adults with transfusion dependent or independent alpha- or beta-thalassemia under the brand name Aqvesme. Additionally, the company announced a U.S. WAC price of $425k annually, modestly above Pyrukynd's WAC price of $335k, and higher than Leerink had forecast.

Truist

Gregory Renza

Buy

maintain

$32 -> $38

2025-12-24

Reason

Truist

Gregory Renza

Price Target

$32 -> $38

2025-12-24

maintain

Buy

Reason

Truist analyst Gregory Renza raised the firm's price target on Agios Pharmaceuticals to $38 from $32 and keeps a Buy rating on the shares after Tuesday night's approval of Aqvesme for patients with NTD and TD alpha-/beta-thalassemia. The firm called Aqvesme's approval in thalassemia "expected but still a relief," in spite of the PDUFA delay.

H.C. Wainwright

Buy

maintain

$48 -> $62

2025-12-24

Reason

H.C. Wainwright

Price Target

$48 -> $62

2025-12-24

maintain

Buy

Reason

H.C. Wainwright raised the firm's price target on Agios Pharmaceuticals to $62 from $48 and keeps a Buy rating on the shares after the company announced FDA approval for mitapivat, marketed in the U.S. as Aqvesme. Following the approval, the firm has updated its model to shift the Aqvesme commercial launch in thalassemia from Q4 of 2025 to Q1 of 2026, consistent with management's guidance, and now models Aqvesme pricing as $425,000 wholesale acquisition cost, compared to a previously estimated $335,000 WAC.

Valuation Metrics

The current forward P/E ratio for Agios Pharmaceuticals Inc (AGIO.O) is -3.73, compared to its 5-year average forward P/E of -1.64. For a more detailed relative valuation and DCF analysis to assess Agios Pharmaceuticals Inc 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

N/A

5Y Average PE

-1.64

Current PE

-3.73

Overvalued PE

6.00

Undervalued PE

-9.27

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

N/A

5Y Average EV/EBITDA

-2.38

Current EV/EBITDA

-0.73

Overvalued EV/EBITDA

-0.22

Undervalued EV/EBITDA

-4.54

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

N/A

5Y Average PS

350.38

Current PS

20.14

Overvalued PS

1594.97

Undervalued PS

-894.22

Financials

Annual

Quarterly

N/A

Total Revenue

N/A

Operating Profit

N/A

Net Income after Tax

N/A

EPS - Diluted

N/A

Free Cash Flow

N/A

Gross Profit Margin - %

N/A

FCF Margin - %

N/A

Net Margin - %

N/A

ROIC

Trading Trends

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

Bought

Hedge Fund

Hedge Funds areBuying! The buying amount has increased 297.63% over the last quarter.

Sold

Bought

Congress Trading

Congress are Neutral. There are no significant trading trends over the last month.

Sold

Bought

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

Bought

AGIO News & Events

Events Timeline

No data

News

8.5

2025-12-27Yahoo Finance

UiPath to Join S&P Midcap 400 Index Effective January 2, 2026

6.0

2025-12-26Benzinga

HC Wainwright Raises Agios Price Target to $62

7.5

2025-12-26NASDAQ.COM

Galectin Secures $10M Credit Line, FDA Provides Guidance on Regulatory Pathway

People Also Watch

Frequently Asked Questions

What is Agios Pharmaceuticals Inc (AGIO) stock price today?

The current price of AGIO is 28.41 USD — it has increased 0.89 % in the last trading day.

What is Agios Pharmaceuticals Inc (AGIO)'s business?

Agios Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on developing and delivering transformative therapies for patients living with rare diseases. It markets a first-in-class pyruvate kinase (PK) activator for adults with PK deficiency, the first disease-modifying therapy for debilitating hemolytic anemia. Its lead product candidate in its portfolio, PYRUKYND (mitapivat), is an activator of both wild-type and mutant pyruvate kinase, or PK, enzymes for the potential treatment of hemolytic anemias. It is also developing tebapivat, a novel PK activator, for the potential treatment of lower-risk myelodysplastic syndromes, or LR MDS, and hemolytic anemias; AG-181, its phenylalanine hydroxylase, or PAH, stabilizer for the potential treatment of phenylketonuria, or PKU; and AG-236, an siRNA in-licensed from Alnylam Pharmaceuticals, Inc., targeting the transmembrane serine protease 6, or TMPRSS6 gene for the potential treatment of polycythemia vera, or PV.

What is the price predicton of AGIO Stock?

What is Agios Pharmaceuticals Inc (AGIO)'s revenue for the last quarter?

Agios Pharmaceuticals Inc revenue for the last quarter amounts to 12.88M USD, increased 43.69 % YoY.

What is Agios Pharmaceuticals Inc (AGIO)'s earnings per share (EPS) for the last quarter?

Agios Pharmaceuticals Inc. EPS for the last quarter amounts to -1.78 USD, decreased -110.97 % YoY.

What changes have occurred in the market's expectations for Agios Pharmaceuticals Inc (AGIO)'s fundamentals?

How many employees does Agios Pharmaceuticals Inc (AGIO). have?

Agios Pharmaceuticals Inc (AGIO) has 486 emplpoyees as of January 10 2026.

What is Agios Pharmaceuticals Inc (AGIO) market cap?

Today AGIO has the market capitalization of 1.66B USD.